Hostname: page-component-7c8c6479df-27gpq Total loading time: 0 Render date: 2024-03-29T14:21:40.840Z Has data issue: false hasContentIssue false

A Controlled Clinical Trial of Meprobamate in the Management of Difficult and Destructive Female Mental Defectives

Published online by Cambridge University Press:  08 February 2018

W. A. Heaton-Ward
Affiliation:
Stoke Park Hospital Group, Bristol
J. Jancar
Affiliation:
Stoke Park Hospital, Bristol

Extract

Meprobamate is the shortened name of 2-Methyl-2-n-Propyl-1,3 propanediol dicarbamate, which is also known as Miltown or Equanil.

Type
Original Articles
Copyright
Copyright © Royal College of Psychiatrists, 1958 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Pennington, W. M., “The effects of six ataraxics in neuropsychiatric patients”. Read at the Ainerican Psychosomatic Society Meeting, New York City, 6–8 October, 1955.Google Scholar
2. Borrus, J. C., “Study of effect of Miltown on psychiatric states”, J.A.M.A., 1955, 157, 1596.Google Scholar
3. Lemere, M., “New tranquillizing drugs”, Northwest Med., 1955, 54, 1098.Google Scholar
4. Selling, L. S., “Clinical study of a new tranquillizing drug; use of Miltown”, J.A.M.A., 1955, 167, 1594.Google Scholar
5. Perlstein, M. A., “Miltown, its use in convulsive and related disorders”, 1956, J.A.M.A., April.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.